Edgen Stock·Dec 02 2025, 02:09返回
返回
Adagene 與 Third Arc Bio 達成癌症治療平台許可協議，價值高達 8.4 億美元
Edgen Stock·Dec 02 2025, 02:09
[1] Adagene 與 Third Arc Bio 簽署許可協議 | The Pharmaletter (https://www.thepharmaletter.com/biotechnology ...)[2] Adagene 宣布與 Third Arc Bio 達成許可協議，用於... (https://finance.yahoo.com/news/adagene-announ ...)[3] Adagene 和 Third Arc Bio 合作開發掩蔽的 CD3 T 細胞... (https://www.ddw-online.com/adagene-and-third- ...)